Medpace Q3 2026 Earnings: The $716M Quarter That Ran on Client Cash

Medpace turned $716.0 million of third-quarter revenue into $137.5 million of net income — a 19.2% net margin, the kind of profitability you expect from a software company, not a contract research organization that runs clinical trials. The mechanism is visible one level down the income statement: clients pay upfront, so the balance sheet carries $961.9 million of advanced billings — 134% of a quarter's revenue — funding a business with no debt, $705.3 million of cash, and a fresh $1.0 billion buyback authorization. Growth was solid rather than spectacular at 8.5%, and the full-year guide implies a flat fourth quarter, so this quarter is really a margin and backlog story. The ledger below shows both.

The Headline Numbers​

Medpace's fiscal year is the calendar year, so every figure below comes from the Form 10-Q for the quarter ended September 30, 2026 and the earnings release furnished as Exhibit 99.1 to the Form 8-K, which agree to the thousand. Net income here and everywhere below is attributable to Medpace Holdings, Inc. — the statements carry no noncontrolling interest, so the filed total needs no deduction.

Two rows do the real work. First, direct costs grew 6.3% against revenue's 8.5% — a 1.4-point improvement in the cost ratio that flows straight to operating margin. Second, net income grew 23.7%, well ahead of operating income's 16.7%, and the gap is almost entirely the tax line: the effective rate fell to 19.6% from 22.2% on larger Foreign Derived Deduction Eligible Income benefits, per the 10-Q. EPS adds one more point on top through a 1.5% smaller diluted share count. So the 25.4% EPS growth decomposes cleanly into operating leverage (about two-thirds) plus tax and buybacks (about one-third).

Medpace reports a single non-GAAP measure, EBITDA, and the bridge is refreshingly short — no stock-comp add-back, no "adjusted" revenue:

That is the whole adjustment. When a company's GAAP-to-non-GAAP bridge fits in five lines, the GAAP number is the story.

Revenue Deep Dive​

Medpace discloses revenue by therapeutic area, and the mix is concentrating fast. Oncology passed Metabolic this quarter as the largest area, and the two together are now 61% of revenue:

The 10-Q's MD&A attributes the growth to "strong activity within the Metabolic, Oncology and Central Nervous System therapeutic areas" — the same three areas it credited for full-year 2025. But the rates tell a changing story inside that sentence. Oncology's 19.4% and CNS's 27.5% are doing the carrying now; Metabolic, which exploded 62.8% in full-year 2025 (from $457.5M to $745.0M), decelerated to 5.0% this quarter. That is the law of large numbers meeting a maturing trial book, and it is the mix shift to watch: two years ago Metabolic was 20% of revenue, and the Q3 print is the first quarter in the ledger where its growth trails the company average.

The other structural fact is what "revenue" contains. Reimbursed out-of-pocket expenses — investigator fees, labs, and other pass-through trial costs Medpace bills back to sponsors — were $287.3 million, or 40.1% of reported revenue. Strip them out and the quarter is $428.7 million of direct-service revenue carrying $165.5 million of operating income: a 38.6% margin on the work Medpace actually performs. Both presentations are honest; the filing's is required, and the stripped one explains why a services business earns software margins. The risk runs the other way too: pass-throughs "can fluctuate significantly from period to period based on the timing of program initiation and closeout," in the 10-Q's words, so a quarter's headline growth can owe more to trial timing than to underlying demand. This quarter it did not — direct service costs grew 9.9% on personnel supporting service growth — but the 40% pass-through share is why backlog, not revenue, is the demand signal here.

On management signals: there are none to scan. The release carries no executive quotes and no commentary on demand, pricing, supply, or the selling environment — it is numbers, guidance, and boilerplate. That absence is itself the finding. Where a release might narrate the demand environment, Medpace publishes the backlog conversion rate (23.8%) and lets it speak. With no pricing language anywhere in the release or the quarter's MD&A, price is not a claimed lever — throughput is.

The Margin Story​

The gross line moved 1.5 points this quarter, and the mechanics are all in direct costs: reimbursed out-of-pocket expenses grew only 3.8% while revenue grew 8.5%, as trial-timing pass-throughs lagged service growth. Personnel costs — the real cost of running trials — grew faster, up $16.2 million or about 8.7% on the direct-service base, roughly in line with revenue. So the gross expansion is a timing benefit, not a productivity breakthrough, and it can reverse in a pass-through-heavy quarter.

Below gross, SG&A is the quiet compounder: $51.8 million is just 7.2% of revenue, down a tenth of a point even as headcount grew. A company running 6,600 people across 46 countries on 7.2% SG&A is the disciplined-operating-model claim made visible — there is simply very little overhead between trial revenue and operating profit. Then the tax line contributes the final point-plus: 19.6% effective versus 22.2% a year ago, already below the 21% statutory rate. That cuts both ways for the forward margin — FDII benefits are real cash savings, but a sub-statutory rate has less room to fall further.

The One Big Question: Is the Backlog Keeping Up With Revenue?​

Backlog grew 5.6% while revenue grew 8.5% in the quarter and 16.9% over nine months. When the future grows slower than the present, the conversion rate does more work — and Medpace's did, at 23.8% of backlog converted this quarter. The question is whether the pipeline is refilling fast enough to sustain double-digit growth.

The refill math answers reassuringly. Awards grew 10.6% — faster than revenue — and the 1.22x book-to-bill means Medpace sold $1.22 of future work for every $1.00 it delivered, slightly better than last year's 1.20x. Backlog coverage of 4.4 quarters is over a year of forward coverage. The apparent gap between backlog growth (+5.6%) and nine-month revenue growth (+16.9%) is mostly a denominator story: revenue accelerated while the backlog base compounded more slowly, and with awards outpacing delivery the stock keeps rising in absolute dollars (+$166.6 million year over year).

The number that would flip this section bearish is the cancellation rate, and Medpace does not disclose it — net awards already reflect cancellations, so a rising gross win rate could be masking rising churn. With no disclosure, the check is the conversion rate itself: if backlog quality were deteriorating, conversion would slip as cancelled work sat unconverted. At 23.8%, it is holding. Watch that rate before you watch the backlog total.

Tracking a $3.2B-Backlog Company in Plain Text​

A CRO's financial statements are a test of double-entry discipline: every dollar of client cash arrives before the work exists, so the balance sheet must show the obligation the income statement has not earned yet. Modeling Medpace in Beancount forces that obligation onto the page — how we model every company — instead of letting it hide in a footnote.

Here is the quarter, as the ledger records it (income negative, expenses positive — Beancount sign conventions):

; FY2026Q3 Income Statement — three months ended September 30, 2026
; Check: −716.000 + 204.851 + 287.264 + 51.765 + 6.425 + 0.155 − 5.366 + 33.446 + 137.460 = 0 ✓
 
2026-09-30 * "Medpace Holdings, Inc." "FY2026Q3 Income Statement"
  Income:Revenue                          -716.000 MUSD  ; revenue, net (incl. 3.8 with related parties; Oncology 229.927 + Metabolic 209.242 + Other 99.955 + CNS 83.649 + Cardiology 61.409 + AVAI 31.818)
  Expenses:CostOfRevenue                   204.851 MUSD  ; direct service costs, excluding depreciation and amortization
  Expenses:CostOfRevenue                   287.264 MUSD  ; reimbursed out-of-pocket expenses (total direct costs 492.115)
  Expenses:SellingGeneralAdministrative     51.765 MUSD  ; selling, general and administrative
  Expenses:OtherNet                          6.425 MUSD  ; depreciation
  Expenses:OtherNet                          0.155 MUSD  ; amortization
  Income:OtherNet                           -5.366 MUSD  ; miscellaneous income 0.017 + interest income 5.349
  Expenses:IncomeTax                        33.446 MUSD  ; income tax provision
  Equity:Adjustments                       137.460 MUSD  ; net income offset, fully attributable (RE set by balance assertion)

The one balance-sheet number that tells the narrative is advanced billings: $961.9 million — 134% of quarterly revenue, and the company's largest liability by far. Those are upfront client fees collected at signing, the float that funds a business with no debt of any kind: no short-term borrowings, no long-term debt, nothing. Against it, cash of $705.3 million and nine-month operating cash flow of $530.4 million (139% of net income) show a company its customers finance. The second number worth a look is the accumulated deficit of $373.6 million beside $584.9 million of positive equity — the scar of $919.2 million of FY2025 buybacks that retired stock faster than earnings accumulated. Medpace funds buybacks from client float, not leverage.

The Multi-Year Arc​

Revenue compounded 15.8% annually from FY2023 to FY2025 while operating margin stepped from 17.9% to a 21%-plus plateau — the operating leverage of a fixed-cost trial platform filling up. Net margin is noisier (15.0% → 19.2% → 17.8%) because interest income and tax swing it around: FY2024's peak rode $25.0 million of interest income that halved the next year. The share count tells the capital-allocation half of the compounding story — down 11.4% from FY2024's 32.01 million to this quarter's 28.37 million — which is why EPS growth keeps beating net-income growth. And advanced billings nearly doubled in under three years, the float growing with the book. The ledger starts at FY2024 because those are the two most recent audited annuals plus the current quarter; FY2023 figures above come from the same 10-K comparatives.

The Verdict: Bull vs. Bear​

Bull Case

• The backlog math supports 2027. A 1.22x book-to-bill on awards growing 10.6% with 4.4 quarters of coverage means double-digit revenue growth is pre-sold, not hoped for.
• Oncology and CNS are re-accelerating the mix. At +19.4% and +27.5%, the two growth areas offset Metabolic's normalization to +5.0% — diversification happening in real time.
• The float funds everything. $961.9 million of advanced billings plus $705.3 million of cash against zero debt means buybacks, capex, and growth need no external capital at any plausible rate.
• EPS compounds on two engines. Operating leverage plus an 11.4% smaller share count in under two years, with a fresh $1.0 billion authorization running through 2028.
• Guidance looks conservative. The full-year revenue range implies a flat Q4 of $705–725 million against Q3's $716 million — a bar Medpace has room to clear if conversion holds at 23.8%.

Bear Case

• Margin expansion is borrowed from timing and tax. The 1.5-point gross gain came from slow pass-through growth that reverses with trial timing, and the 19.6% tax rate sits below statutory with FDII benefits doing the work — neither is a durable lever.
• Backlog growth trails revenue growth by 11 points over nine months. Awards cover it today, but if book-to-bill slips below 1.1x for two straight quarters, the 4.4x coverage starts visibly eroding.
• 61% of revenue rides two therapeutic areas. An Oncology trial failure wave or a Metabolic sponsor pullback — the areas grew 15% and 63% respectively in FY2025 — concentrates cancellation risk the filing does not quantify.
• No disclosure, no verification. Medpace publishes no cancellation rate, no RFP-flow commentary, and no executive outlook beyond guidance numbers. The 23.8% conversion rate is the only quality signal, and it arrives quarterly.
• The flat-Q4 guide may be telling the truth. If Q4 revenue lands at the $715 million midpoint, full-year growth of 12.4% confirms deceleration from 20.0% — priced for a compounder, delivering a normal year.

Our Take: Buy the machine, watch the conversion rate. Medpace is the rare CRO where the balance sheet — client float, no debt, a shrinking share count — is a stronger asset than any single quarter's growth rate, and 1.22x book-to-bill says the top line is funded into 2027. But 19.2% net margins built partly on timing and tax deserve a skeptical eye, and with no management color beyond the numbers, the 23.8% backlog conversion rate is the single quarterly figure that decides whether this thesis holds. Above 22%, the machine compounds; below it, the backlog is telling you something the release never will.